Tafinlar Plus Mekinist Approved for Pediatric BRAF V600E Low-Grade Glioma
The FDA approved the combination to treat pediatric patients 1 year of age and older who have low-grade glioma with a BRAF V600E mutation and require systemic therapy.
The FDA approved the combination to treat pediatric patients 1 year of age and older who have low-grade glioma with a BRAF V600E mutation and require systemic therapy.
In the US, AYAs with cancer face high economic and human costs throughout their lifetime.
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Maternal infections, especially genital and urinary tract infections, during pregnancy are associated with an increased risk of childhood leukemia in offspring, a study suggests.
Increasing social vulnerability is associated with significant decreases in surveillance and survival time among pediatric patients with head and neck cancers.
Survivors of pediatric cancer have a higher rate of clonal hematopoiesis than their peers at any age, a study suggests.
Collaboration between parents and nurses is essential to the care of children with neuroblastoma receiving 131I-MIBG, a study suggests.
Medication errors may be common in children with leukemia or lymphoma, and these errors can lead to serious harm, a new study suggests.
Creative arts therapy can ease procedural anxiety in pediatric patients undergoing their first year of cancer treatment, a study suggests.